Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background Elevated pulse pressure (PP), indicative of arterial stiffness, has been implicated in cognitive impairment and Alzheimer's disease (AD) pathology. However, its role in preclinical AD and interactions with genetic risk factors like apolipoprotein E ε4 (APOE4) remain unclear. Objectives To investigate the association between baseline PP and AD biomarkers (amyloid-beta (Aβ) and tau) and cognitive decline, and to determine whether APOE4 carrier status moderates these relationships. Design Prospective cohort study and secondary analysis of the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) randomized clinical trial SETTING: Multicenter observational cohort and randomized clinical trial conducted at 67 sites across the United States, Canada, Australia, and Japan. Participants This study included 1690 cognitively unimpaired older adults from the A4 and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) studies. Participants underwent baseline PP assessment, Aβ and tau PET imaging, and cognitive testing with longitudinal follow-up over 240 weeks. Measurements Blood pressure was measured at baseline, with PP calculated as the difference between systolic and diastolic pressures. AD pathologies were assessed through Aβ PET imaging using 18F-Florbetapir, and regional tau deposition in inferior temporal and meta-temporal regions using 18F-Flortaucipir PET imaging. Cognitive performance was measured using the Preclinical Alzheimer Cognitive Composite (PACC). Results Higher baseline PP was significantly associated with increased Aβ (β = 0.078; p = 0.001), inferior temporal tau (β = 0.110; p = 0.032), and meta-temporal tau deposition (β = 0.116; p = 0.022). In longitudinal analyses, elevated PP predicted greater decline in PACC scores (β = -0.020; p Conclusions Elevated PP is associated with increased AD biomarker burden and accelerated cognitive decline in cognitively unimpaired older adults, particularly among APOE4 carriers. Our study suggests that arterial stiffness may contribute to AD pathogenesis and progression via tau pathology. These results highlight the potential of vascular health management as an early intervention target for AD prevention, especially in genetically at-risk populations.

What this study adds

Evidence grade: High

This is a follow-up (cohort) study of 1,690 participants. In 1,690 cognitively unimpaired older adults, higher pulse pressure was associated with more amyloid and tau on PET scans and faster cognitive decline, especially in APOE4 carriers. This is an observational finding about a risk marker, not evidence that lowering pulse pressure prevents Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Jung, J. H., Kong, N., Lee, S., & A4 and LEARN Study Teams. (2025). Pulse pressure as a predictor of Alzheimer's disease biomarkers and cognitive decline: The moderating role of APOE ε4. The journal of prevention of Alzheimer's disease. https://doi.org/10.1016/j.tjpad.2025.100363

Vancouver

Jung JH, Kong N, Lee S, A4 and LEARN Study Teams. Pulse pressure as a predictor of Alzheimer's disease biomarkers and cognitive decline: The moderating role of APOE ε4. The journal of prevention of Alzheimer's disease. 2025. doi:10.1016/j.tjpad.2025.100363. PMID: 40908201.

BibTeX

@article{jung2025-40908201,
  author  = {Jung, J. H. and Kong, N. and Lee, S. and {A4 and LEARN Study Teams}},
  title   = {{Pulse pressure as a predictor of Alzheimer's disease biomarkers and cognitive decline: The moderating role of APOE ε4}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2025},
  doi     = {10.1016/j.tjpad.2025.100363},
  pmid    = {40908201},
  url     = {https://doi.org/10.1016/j.tjpad.2025.100363}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In 1,690 cognitively unimpaired older adults, higher pulse pressure was associated with more amyloid and tau on PET scans and faster cognitive decline, especially in APOE4 carriers. This is an observational finding about a risk marker, not evidence that lowering pulse pressure prevents Alzheimer's disease.

Study details

How this study scored 62/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 3 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 1 of 2; Times cited 2 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 0 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 62 of 100.62 of 100 points earned38 not earned

Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (The journal of prevention of Alzheimer's disease)
Journal's citation record 0 / 4 The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomized controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 3 / 4 1,690 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited 2 / 7 Cited 10 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 3.3 citations a year over 3 year(s) since 2025
Impact for its field and year 3 / 6 Cited 6.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 1 / 4 Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Seung‐Hoon Lee: h-index 80 (OpenAlex, whole career)
Institution's track record 0 / 3 Hanyang University: institution h-index 548 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40908201)
Free to read 2 / 2 Free to read
Total 62 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Treatments from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →